Protecting Patient Access to Cancer and Complex Therapies Act
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsors
- 50
- Latest action
- Jul 7, 2025
What it does
The bill amends the Social Security Act to require manufacturers of selected drugs and biological products subject to maximum fair price negotiation to provide rebates when ASP+6 payments exceed MFP+6 payments, with rebates calculated based on quarterly utilization and deposited into the Federal Supplementary Medical Insurance Trust Fund. It affects drug manufacturers, Medicare Part B beneficiaries receiving these drugs, and the Secretary of Health and Human Services, who must provide utilization data to manufacturers and enforce compliance. The bill also adjusts beneficiary coinsurance to be based on MFP+6 amounts for rebated drugs and includes conforming amendments to ensure consistent…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
Where it goes next
While a bill can still move, the questions are about people and money.